An innovative drug discovery company
General Intermediates Canada (GIC) began in Edmonton 40 years ago as a small molecule CMO.
The company sold its proprietary, cutting edge small molecules globally, all the while performing extensive self-funded R&D work that was never published or patented.
Today, the company is under new ownership with a revamped strategy and a mandate to grow. The organization has been active in performing in silico testing of its legacy R&D work and advancing the most promising findings as well as new discoveries. This work covers the gamut of human disease profiles.